PLEK2

Across TCGA pan-cancer cohorts, PLEK2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of PLEK2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PLEK2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PLEK2 is over-expressed in tumor.

HNSC, CCRCC, and PDAC are the cancer types where PLEK2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLEK2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.854	<.001	11	view →
CCRCC	Male	III,IV	+0.615	<.001	11	view →
PDAC	Male	All	+1.068	<.001	9	view →
LSCC	Male	III,IV	+0.780	<.001	8	view →
LUAD	Female	All	+0.681	<.001	8	view →
COAD	All	II,III,IV	+0.194	.032	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

PLEK2–HNSC

Open the HNSC breakdown →